Streetbeat News

Revenues

APEI

American Public Education anticipates its full-year 2024 consolidated revenue to be between $610 million and $620 million, closely aligning with the estimated $613.725 million.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:53 pm

APEI

American Public Education anticipates Q1 consolidated revenue between $151M-$153M, surpassing the estimated $150.6M. However, it expects a loss per share of $(0.25)-$(0.17), contrary to the estimated earnings of $0.04 per share.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:51 pm

FHTX

Foghorn Therapeutics Inc. (FHTX) announced its participation in the 2024 AACR Annual Meeting with presentations on its pipeline programs, including preclinical data for FHD-909, a potential first-in-class BRM selective inhibitor. The company will present data on the efficacy and safety of FHD-909 and other programs such as selective CBP and EP300 degraders, showcasing significant anti-tumor activity and long-acting degrader capabilities for up to once-a-month dosing. IND filing for FHD-909 is planned in Q2 2024.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:51 pm

BNGO

Bionano Genomics (BNGO) projects Q1 revenue of $8.25M-$8.75M, below the $9.69M estimate, and FY24 revenue of $37M-$41M, under the $47.17M estimate. The company is restructuring debt and phasing out non-core products, expecting to install 80-100 new OGM systems in 2024.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:50 pm

MLNK

MeridianLink projects its Q1 2024 revenue to be between $75M and $78M, which is below the estimated $81.631M.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:45 pm

OOMA

Ooma projects its Q1 adjusted EPS to be between $0.11 and $0.12, aligning with the $0.11 estimate. However, its forecast for FY25 revenue ranges from $0.51 to $0.55 billion, falling short of the $0.61 billion estimate.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:44 pm

CERS

Cerus Corporation projects its FY24 revenue to be between $172M and $175M, which is below the estimated $185.871M.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:42 pm

GILD

Gilead Sciences, Inc. (NASDAQ:GILD) announced new real-world data supporting the use of Veklury (remdesivir) for hospitalized COVID-19 patients, presented at the 31st Conference on Retroviruses and Opportunistic Infections. The data show Veklury's association with reduced long-COVID symptoms and mortality, especially among immunocompromised patients. One study highlighted a 10% lower risk of post-COVID conditions with Veklury use. Another analysis from the Omicron era indicated a 25% lower mortality risk among immunocompromised patients treated with Veklury. Additionally, a combination of Veklury and dexamethasone was associated with significantly lower mortality compared to dexamethasone alone, across various oxygen requirements.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:42 pm

FTEL

Fitell Corporation (NASDAQ:FTEL), an Australian online retailer of gym and fitness equipment, reported a significant decrease in H1 revenue and gross profit for the period ending December 31, 2023. Revenue fell by 30.5% to $2.1M, and gross profit dropped by 46.8% to $0.85M compared to the same period in 2022. The decline was attributed to decreased merchandise revenue, absence of sales in consumable products, and reduced licensing income. Despite a 34.3% increase in sales orders, the average revenue per order fell by 30.5%, mainly due to consumer spending changes. The company also faced increased expenses, including consulting fees and general and administrative costs, leading to a net loss of $2.66M, significantly higher than the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:41 pm

PKOH

ParkOhio anticipates its 2024 revenues to grow in the mid-single digit range year-over-year, primarily due to strong demand in Supply Technologies and robust backlogs in Engineered Products.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:41 pm